NCT02468375View on ClinicalTrials.gov

Prospective Study for Patient Perception of Treatment Satisfaction After Switching to Mirabegron in Patients With Overactive Bladder Who Were Unsatisfied With Efficacy of Antimuscarinic Therapy or Adverse Event.

PHASE4CompletedINTERVENTIONAL

Enrollment

434

Participants

Timeline

Start Date

June 30, 2015

Primary Completion Date

October 31, 2017

Study Completion Date

December 31, 2017

Conditions

Overactive Bladder

Interventions

DRUG

mirabegron 50mg

434 OAB patient intake mirabegron 50mg/day for 12 weeks.

Trial Locations (1)

130-710

Samsung Medical Center, Seoul

All Listed Sponsors

lead

Samsung Medical Center

OTHER

NCT02468375 - Prospective Study for Patient Perception of Treatment Satisfaction After Switching to Mirabegron in Patients With Overactive Bladder Who Were Unsatisfied With Efficacy of Antimuscarinic Therapy or Adverse Event. | Biotech Hunter | Biotech Hunter